The FDA on June 7, 2018 approved MIRCERA® for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA. MIRCERA® is a product of Vifor Pharma Inc.
Bottom Ad
Advertisement
Subscribe
